hotspot -WSS

hotspot

author：comprehensive 2025-09-28 21:05:37 - browse：72

A sign of Gilead Sciences sits in front of its headquarter and next to a pedestrian crossing sign — health coverage from STAT — Justin Sullivan/Getty Images

The assault on the development of new lifesaving therapies continues apace. Recently, the First Appellate Division of California Appeals held that companies not only have to defend products they have developed and marketed, but also those they have not.

In 2001, Gilead secured FDA approval of tenofovir disoproxil fumarate (TDF), one of first medicines to treat HIV — a product still on the market, despite the potential side effect of causing skeletal and kidney damage. In the years that followed, the company invested in research leading to additional TDF-based regimens critical to the fight against HIV. It had also done preliminary work on a similar but different drug — tenofovir alafenamide fumarate (TAF) — for which it had early, although not definitive, evidence for safety and efficacy.

Ultimately, this medicine was shown to have a better side effect profile than TDF. Starting in 2018, plaintiffs began suing Gilead for negligently failing to develop TAF earlier, on the theory that it wanted to protect the profits from TDF. Now, the California court has agreed to let the suit proceed.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Readout Newsletter: BridgeBio, Akero, and human embryo models

focus

WSS

Digital health funding stays low as a new reality sets in

First over

Watch the official trailer for 'Ahsoka' series

Families look for replacement for GSK asthma drug Flovent

Kerry to visit Beijing for climate talks amid efforts to revive relations between US and China

How are insurers handling Leqembi and related scans?

hotspot

hotspot

explore

After affirmative action ruling, medical educators look to 'holistic review'

Microsoft's Peter Lee: Generative AI could help doctors be more human

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Harvard's David Sinclair gets blowback over aging

The cancer drug shortage isn’t new — and neither are the solutions

For AI in health care standards, federal regulators join with industry group

At least 13 dead in Texas as scorching temps continue

First over

Tori Bowie and the unacceptable rates of Black maternal death

The debate over Covid

focus

A Greenpeace activist is fined for crash

For AI in health care standards, federal regulators join with industry group

Fetal cell organoids grown from amniotic fluid, study finds

Why Talkspace is targeting Medicare, a tricky market

Microsoft's Peter Lee: Generative AI could help doctors be more human

The debate over Covid

focus

focus

leisure time

Wikipedia